Trial · NCT02969655
Results by group163
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 163
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Daprodustat | 10.89 | Standard Error 0.062 | Grams per deciliter (g/dL) | |
| Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Darbepoetin Alfa | 10.83 | Standard Error 0.060 | Grams per deciliter (g/dL) | |
| Percentage of Participants With Mean Hgb in the Target Range (10.0-12.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Daprodustat | Responder | 88 | Percentage of participants | |
| Percentage of Participants With Mean Hgb in the Target Range (10.0-12.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Darbepoetin Alfa | Responder | 90 | Percentage of participants | |
| Percentage of Participants With Mean Hgb in the Target Range (10.0-12.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Daprodustat | Non-responder | 13 | Percentage of participants | |
| Percentage of Participants With Mean Hgb in the Target Range (10.0-12.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) | Darbepoetin Alfa | Non-responder | 10 | Percentage of participants | |
| Change From Baseline in Hgb (Hgb Increase Rate) at Week 4 | Daprodustat | -0.42 | Standard Deviation 0.898 | g/dL | |
| Change From Baseline in Hgb (Hgb Increase Rate) at Week 4 | Darbepoetin Alfa | 0.08 | Standard Deviation 0.525 | g/dL | |
| Percentage of Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat | <= -2.0 | 5 | Percentage of participants | |
| Percentage of Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat | > -2.0 and <= -1.0 | 21 | Percentage of participants | |
| Percentage of Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat | > -1.0 and <= 0 | 44 | Percentage of participants | |
| Percentage of Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat | > 0 and <= 1.0 | 27 | Percentage of participants | |
| Percentage of Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat | > 1.0 and <= 2.0 | 4 | Percentage of participants | |
| Percentage of Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat | > 2.0 | 0 | Percentage of participants | |
| Percentage of Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat | within +/- 1.0 | 75 | Percentage of participants | |
| Percentage of Participants by Hgb Change From Baseline Category at Week 4 | Daprodustat | over +/- 2.0 | 5 | Percentage of participants | |
| Distribution of Daprodustat Dose Level by Visit | Daprodustat | Day 1, n=133 | 4.0 | Inter-Quartile Range 4.0 to 4.0 | milligrams per day (mg/day) |
| Distribution of Daprodustat Dose Level by Visit | Daprodustat | Week 4, n=133 | 4.0 | Inter-Quartile Range 4.0 to 6.0 | milligrams per day (mg/day) |
| Distribution of Daprodustat Dose Level by Visit | Daprodustat | Week 8, n=126 | 4.0 | Inter-Quartile Range 4.0 to 6.0 | milligrams per day (mg/day) |
| Distribution of Daprodustat Dose Level by Visit | Daprodustat | Week 12, n=125 | 6.0 | Inter-Quartile Range 4.0 to 6.0 | milligrams per day (mg/day) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02969655/results